IDEAS home Printed from https://ideas.repec.org/r/oup/rfinst/v35y2022i2p636-679..html
   My bibliography  Save this item

Missing Novelty in Drug Development

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Margaret K. Kyle, 2020. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," Innovation Policy and the Economy, University of Chicago Press, vol. 20(1), pages 95-123.
  2. Brunner, Philipp & Letina, Igor & Schmutzler, Armin, 2024. "Research joint ventures: The role of financial constraints," European Economic Review, Elsevier, vol. 165(C).
  3. Joshua Graff Zivin & Elizabeth Lyons, 2021. "The Effects of Prize Structures on Innovative Performance," AEA Papers and Proceedings, American Economic Association, vol. 111, pages 577-581, May.
  4. Sabrina T. Howell & Jason Rathje & John Van Reenen & Jun Wong, 2021. "Opening up military innovation: causal effects of reforms to U.S. defense research," POID Working Papers 004, Centre for Economic Performance, LSE.
  5. Oliver, Edward & Kourouklis, Dimitrios & Jofre-Bonet, Mireia, 2024. "Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach," Research Policy, Elsevier, vol. 53(8).
  6. Pierre Azoulay & Danielle Li, 2020. "Scientific Grant Funding," NBER Working Papers 26889, National Bureau of Economic Research, Inc.
  7. VEUGELERS Reinhilde & AMARAL-GARCIA Sofia, 2025. "Financing EU Health Innovation: the role of Venture Capital," JRC Working Papers on Corporate R&D and Innovation 2025-01, Joint Research Centre.
  8. Richard Carson & Joshua S. Graff Zivin & Jordan Louviere & Sally Sadoff & Jeffrey G. Shrader Jr, 2020. "The Risk of Caution: Evidence from an R&D Experiment," NBER Working Papers 26847, National Bureau of Economic Research, Inc.
  9. Evaluator 2, 2025. "Evaluation 2 of "Pharmaceutical Pricing and R&D as a Global Public Good"," The Unjournal Evaluations 2025-30, The Unjournal.
  10. repec:cdl:ucsdec:qt8637337w is not listed on IDEAS
  11. Joonkyu Choi & Serguey Braguinsky & Yuheng Ding & Karam Jo & Seula Kim, 2023. "Mega Firms and New Technological Trajectories in the U.S," NBER Working Papers 31460, National Bureau of Economic Research, Inc.
  12. Howell, Sabrina T. & Rathje, Jason & Van Reenen, John & Wong, Jun, 2021. "Opening up Military Innovation: Causal Effects of 'Bottom-up' Reforms to U.S. Defense Research," IZA Discussion Papers 14297, Institute of Labor Economics (IZA).
  13. Lo, Andrew W. & Thakor, Richard T., 2023. "Financial intermediation and the funding of biomedical innovation: A review," Journal of Financial Intermediation, Elsevier, vol. 54(C).
  14. Malek, Jan & Newham, Melissa & Seldeslachts, Jo & Veugelers, Reinhilde, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," CEPR Discussion Papers 18816, C.E.P.R. Discussion Papers.
  15. Gaurab Aryal & Federico Ciliberto & Leland E. Farmer & Ekaterina Khmelnitskaya, 2022. "Valuing Pharmaceutical Drug Innovations," Papers 2212.07384, arXiv.org, revised Apr 2024.
  16. Friedrich, Benjamin U. & Zator, Michał, 2023. "Flexibility costs of debt: Danish exporters during the cartoon crisis," Journal of Financial Economics, Elsevier, vol. 148(2), pages 91-117.
  17. Arts, Sam & Hou, Jianan & Gomez, Juan Carlos, 2021. "Natural language processing to identify the creation and impact of new technologies in patent text: Code, data, and new measures," Research Policy, Elsevier, vol. 50(2).
  18. Jan Starmans, 2023. "Technological Determinants of Financial Constraints," Management Science, INFORMS, vol. 69(5), pages 3003-3024, May.
  19. Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
  20. Filippo Mezzanotti, 2021. "Roadblock to Innovation: The Role of Patent Litigation in Corporate R&D," Management Science, INFORMS, vol. 67(12), pages 7362-7390, December.
  21. Anckaert, Paul-Emmanuel, 2025. "When the drugs (don’t) work: The role of science in product commercialization," Research Policy, Elsevier, vol. 54(5).
  22. David Dranove & Craig Garthwaite & Manuel Hermosilla, 2022. "Does consumer demand pull scientifically novel drug innovation?," RAND Journal of Economics, RAND Corporation, vol. 53(3), pages 590-638, September.
  23. Joshua L. Krieger & Xuelin Li & Richard T. Thakor, 2022. "Find and Replace: R&D Investment Following the Erosion of Existing Products," Management Science, INFORMS, vol. 68(9), pages 6552-6571, September.
  24. Pierre Azoulay & Danielle Li, 2020. "Scientific Grant Funding," NBER Chapters, in: Innovation and Public Policy, pages 117-150, National Bureau of Economic Research, Inc.
  25. Li, Xuelin & Liu, Tong & Taylor, Lucian A., 2023. "Common ownership and innovation efficiency," Journal of Financial Economics, Elsevier, vol. 147(3), pages 475-497.
  26. Wagner, Stefan & Sternitzke, Christian & Walter, Sascha, 2022. "Mapping Markush," Research Policy, Elsevier, vol. 51(10).
  27. Kyle Myers & Wei Yang Tham, 2023. "Money, Time, and Grant Design," Papers 2312.06479, arXiv.org.
  28. Filippo Mezzanotti & Timothy Simcoe, 2023. "Research and/or Development? Financial Frictions and Innovation Investment," Working Papers 23-39, Center for Economic Studies, U.S. Census Bureau.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.